Stockreport

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter [Yahoo! Finance]

Aytu BioPharma, Inc.  (AYTU) 
NASDAQ:AMEX Investor Relations: aytubio.com/investors/stock-information
PDF Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 million Q2 2024 ADHD Portfolio net revenue up 49% compared to [Read more]